12:00 AM
 | 
Jun 07, 2010
 |  BioCentury  |  Finance

Next Show for Prolia

Amgen's Prolia OK'd for osteoporosis, but investors banking on good cancer data

After last week's FDA approval of Prolia denosumab from Amgen Inc. to treat postmenopausal osteoporosis, buysiders are focused on upcoming data and an approval in oncology, which they expect could be a more lucrative market due higher dosing and more frequent treatment.

First up are Phase III data to prevent or delay bone metastases in prostate cancer patients. Results are expected next half. Next is an anticipated approval late this year or early next for Prolia to reduce skeletal related events (SREs) in cancer patients. Amgen (NASDAQ:AMGN) submitted a BLA to FDA for that indication last month (see BioCentury, May 17).

"The largest potential indication that has investors' attention currently is the use of denosumab for the prevention of bone metastases in prostate cancer," said Paul Wagner of Allianz RCM. "We should get that data in 2H10. If it's positive, Prolia could have blockbuster revenue potential, which is...

Read the full 735 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >